Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.80, $0.27 better than the analyst estimate of $0.53. Revenue for the quarter came in at $370.2 million versus the consensus estimate of $347.98 million.

• The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and ongoing variability in the recovery in surgical procedure volumes.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.